Holen Sie sich die Stockscreener-App
4.78
4.40%
-0.22
Handel nachbörslich:
4.76
-0.02
-0.42%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AVXL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$5.00
Offen:
$5
24-Stunden-Volumen:
917.55K
Relative Volume:
0.53
Marktkapitalisierung:
$442.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-48.17M
KGV:
-8.386
EPS:
-0.57
Netto-Cashflow:
$-37.10M
1W Leistung:
+7.17%
1M Leistung:
+25.46%
6M Leistung:
-49.15%
1J Leistung:
-45.25%
1-Tages-Spanne:
$4.695
$5.0199
1-Wochen-Bereich:
$4.28
$5.1762
52-Wochen-Spanne:
$2.86
$13.99
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Firmenname
Anavex Life Sciences Corporation
Sektor
Branche
Telefon
844-689-3939
Adresse
630 5TH AVENUE, NEW YORK
Compare AVXL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
4.78 | 463.36M | 0 | -48.17M | -37.10M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-09-23 | Eingeleitet | BTIG Research | Buy |
| 2020-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-28 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-02-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-18 | Eingeleitet | Janney | Buy |
| 2018-05-16 | Fortgesetzt | Maxim Group | Buy |
| 2018-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-13 | Bestätigt | Maxim Group | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-02-07 | Eingeleitet | Noble Financial | Buy |
| 2016-03-29 | Eingeleitet | FBR Capital | Outperform |
Alle ansehen
Anavex Life Sciences Corporation Aktie (AVXL) Neueste Nachrichten
Anavex Life Sciences Touts Oral Alzheimer’s Drug Blarcamesine Data, Cash Runway at Healthcare Conference - Yahoo Finance
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Passes Above Fifty Day Moving AverageWhat's Next? - MarketBeat
What's Going On With Anavex Life Sciences Stock On Wednesday? - Benzinga
Anavex Life Sciences to Present at the Citizens Life Sciences Conference - Anavex Life Sciences
Alzheimer's-focused Anavex CEO to speak at Citizens Life Sciences Conference - Stock Titan
Anavex Life Sciences Corp. (AVXL): Investor Outlook on a Biotechnology Stock with a Potential 393% Upside - DirectorsTalk Interviews
Anavex Adds Veteran Healthcare Leader to Board of Directors - The Globe and Mail
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference - Bitget
Anavex Life Sciences Corp. CEO to Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026 - Quiver Quantitative
Alzheimer’s treatment developer Anavex to speak at TD Cowen health conference - Stock Titan
Anavex Life Sciences (NASDAQ:AVXL) Shares Cross Below 50-Day Moving AverageHere's What Happened - MarketBeat
EBITDA per share of Anavex Life Sciences Corp. – LSE:0HFR - TradingView
Anavex Life Sciences appoints Dr. Axel Paeger to board By Investing.com - Investing.com India
Anavex Life Sciences appoints Dr. Axel Paeger to board - Investing.com
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors - marketscreener.com
Anavex Life Sciences Corp. (AVXL) Stock Analysis: Unveiling a Remarkable 433.98% Potential Upside - DirectorsTalk Interviews
Why analysts upgrade Anavex Life Sciences Corp. stockAnalyst Upgrade & AI Powered Buy/Sell Recommendations - mfd.ru
Anavex Life Sciences (NASDAQ:AVXL) Upgraded at Wall Street Zen - MarketBeat
Anavex Life Sciences Corp. (AVXL): Unlocking a 461% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Q2 EPS Forecast for Anavex Life Sciences Boosted by Analyst - MarketBeat
How cyclical is Anavex Life Sciences Corp.’s revenue stream2025 Earnings Impact & Community Trade Idea Sharing Platform - mfd.ru
Is Anavex Life Sciences Corp. stock undervalued right nowGDP Growth & Stock Market Timing Techniques - mfd.ru
HC Wainwright Reaffirms Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2026 Earnings Call Transcript - Insider Monkey
Breakeven On The Horizon For Anavex Life Sciences Corp. (NASDAQ:AVXL) - Yahoo Finance
Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory (NASDAQ:AVXL) - Seeking Alpha
D. Boral Capital Reiterates "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences reports fiscal 2026 first quarter financial results and provides business update - marketscreener.com
Anavex Life Sciences Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Anavex Life Sciences beats EPS forecast in Q1 2026 - Investing.com India
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot - kare11.com
ANAVEX LIFE SCIENCES ($AVXL) Releases Q1 2026 Earnings - Quiver Quantitative
Anavex Life Sciences : Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update - marketscreener.com
Anavex Life Sciences's Earnings Outlook - Benzinga
Anavex Life Sciences (AVXL) to Release Earnings on Wednesday - MarketBeat
Alzheimer’s drug developer Anavex schedules Feb. 9 results call - Stock Titan
Anavex And Alzheimer's Disease: The Future Never Seems To Be Now - Seeking Alpha
Chipmakers Recap: Does Unity Bancorp Inc meet Warren Buffetts criteriaJuly 2025 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Anavex Life Sciences (NASDAQ:AVXL) Stock Passes Above 50-Day Moving AverageHere's Why - MarketBeat
Anavex Life Sciences (AVXL) Price Target Decreased by 25.00% to 33.66 - MSN
H.C. Wainwright reiterates Buy rating on Anavex Life Sciences stock - Investing.com
H.C. Wainwright reiterates Buy rating on Anavex Life Sciences stock By Investing.com - Investing.com Nigeria
Anavex Life Sciences Highlights Oral Alzheimer’s Drug Blarcamesine, Precision Strategy at JPM Conference - MarketBeat
Trading Action: Can Anavex Life Sciences Corp weather a recessionDollar Strength & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Returns Recap: Why Anavex Life Sciences Corp. stock could rally in 2025Market Risk Report & Momentum Based Trading Ideas - Bộ Nội Vụ
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease - Anavex Life Sciences
Anavex Life Sciences Corp. Joins ACCESS-AD Initiative to Support Innovative Alzheimer's Disease Treatments in Europe - Quiver Quantitative
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - Eastern Progress
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm - Eastern Progress
Finanzdaten der Anavex Life Sciences Corporation-Aktie (AVXL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anavex Life Sciences Corporation-Aktie (AVXL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thomas Steffen | Director |
Jun 05 '25 |
Option Exercise |
1.76 |
50,000 |
88,000 |
55,000 |
| MISSLING CHRISTOPHER U | President and CEO |
Mar 24 '25 |
Option Exercise |
0.92 |
500,000 |
460,000 |
1,750,210 |
3.69%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):